{
  "id": "5e2f0afcfbd6abf43b000028",
  "type": "factoid",
  "question": "Which receptor is inhibited by Tivozanib?",
  "ideal_answer": "Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 tyrosine kinases.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29716948",
    "http://www.ncbi.nlm.nih.gov/pubmed/28287096",
    "http://www.ncbi.nlm.nih.gov/pubmed/23252559",
    "http://www.ncbi.nlm.nih.gov/pubmed/25908516",
    "http://www.ncbi.nlm.nih.gov/pubmed/28383032",
    "http://www.ncbi.nlm.nih.gov/pubmed/23818763",
    "http://www.ncbi.nlm.nih.gov/pubmed/25895472",
    "http://www.ncbi.nlm.nih.gov/pubmed/27771610",
    "http://www.ncbi.nlm.nih.gov/pubmed/28971328",
    "http://www.ncbi.nlm.nih.gov/pubmed/25591799",
    "http://www.ncbi.nlm.nih.gov/pubmed/24295377",
    "http://www.ncbi.nlm.nih.gov/pubmed/27128461",
    "http://www.ncbi.nlm.nih.gov/pubmed/29547835",
    "http://www.ncbi.nlm.nih.gov/pubmed/23013465",
    "http://www.ncbi.nlm.nih.gov/pubmed/24019545",
    "http://www.ncbi.nlm.nih.gov/pubmed/27853960",
    "http://www.ncbi.nlm.nih.gov/pubmed/30084668",
    "http://www.ncbi.nlm.nih.gov/pubmed/23701975",
    "http://www.ncbi.nlm.nih.gov/pubmed/23679664",
    "http://www.ncbi.nlm.nih.gov/pubmed/27128217",
    "http://www.ncbi.nlm.nih.gov/pubmed/21976547",
    "http://www.ncbi.nlm.nih.gov/pubmed/22493422"
  ],
  "snippets": [
    {
      "text": "The addition of VEGF-R inhibitor Tivozanib to these systems abrogated the tension-induced paracrine effects on VECs and subsequently impaired BMSC osteogenesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29716948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2\u00a0and 3 tyrosine kinases. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29547835",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a selective inhibitor of all three VEGFRs, with limited off-target interaction, which demonstrates efficacy with improved tolerability relative to multikinase VEGFR-TKIs. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30084668",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFR\u03b1/\u03b2 and cKIT. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27771610",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27853960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cycle arrest and apoptotic cell death. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28383032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGF TKI).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23679664",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23701975",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27853960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We investigated the effects of tivozanib, an oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization (CNV) in mice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23701975",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE\n\nTivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24019545",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent inhibitor of VEGF-1, -2 and -3 receptors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Altogether, these findings suggest that VEGFR blockade by tivozanib has potential anti-glioma effects in vitro.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28287096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib hydrochloride monohydrate (tivozanib; formerly KRN-951, AV-951) is a potent pan-VEGF receptor tyrosine kinase inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23252559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib hydrochloride monohydrate ( tivozanib; formerly KRN-951 , AV-951 ) is a potent pan-VEGF receptor tyrosine kinase inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23252559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent , selective inhibitor of VEGF receptors 1 , 2 , and 3 , with a long half-life",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27128217",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent inhibitor of VEGF-1 , -2 and -3 receptors",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-1 ( VEGFR1) , -2 ( VEGFR2) , and -3 ( VEGFR3",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25908516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Among other VEGF TKIs , tivozanib stands apart due to its selective kinase inhibitory properties as well as its high potency for inhibiting VEGF receptors 1 and 2",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib hydrochloride ( tivozanib ) is a potent , selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 , 2 , and 3 , with a long half-life",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27128461",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib ( Fotivda ) is an oral , potent and highly selective vascular endothelial growth factor receptor ( VEGFR ) inhibitor that has been approved in the EU , Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma ( RCC ) and for adult patients who are VEGFR and mammalian target of rapamycin ( mTOR ) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent and highly specific orally available , tyrosine kinase inhibitor that targets vascular endothelial growth factor ( VEGF ) receptor-1 , VEGF receptor-2 , and VEGF receptor-3 at very low concentrations with a long half-life ( 4\u00a0days",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25895472",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a novel vascular endothelial growth factor receptor tyrosine kinase inhibitor ( VEGF TKI",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib hydrochloride ( tivozanib ) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent and highly specific orally available, tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF) receptor-1, VEGF receptor-2, and VEGF receptor-3 at very low concentrations with a long half-life (4\u00a0days).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25895472",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we show that tivozanib, a pan-inhibitor of vascular endothelial growth factor (VEGF) receptors, inhibited proliferation of GBM cells through a G2/M cell cycle arrest via inhibition of polo-like kinase 1 (PLK1) signalling pathway and down-modulation of Aurora kinases A and B, cyclin B1 and CDC25C.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28287096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent inhibitor of VEGF-1, -2 and -3 receptors.MATERIALS &",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent, selective inhibitor of VEGF receptors 1, 2, and 3, with a long half-life.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27128217",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent and highly specific orally available, tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF) receptor-1, VEGF receptor-2, and VEGF receptor-3 at very low concentrations with a long half-life (4\u00a0days).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25895472",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21976547",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTRODUCTION: Tivozanib is a novel tyrosine kinase inhibitor (TKI) which inhibits vascular endothelial growth factor (VEGF) receptors-1, -2, and -3 at nanomolar concentrations.AREAS",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013465",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was assessed in patients with advanced/metastatic renal cell carcinoma (RCC).PATIENTS AND",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22493422",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we show that tivozanib, a pan-inhibitor of vascular endothelial growth factor (VEGF) receptors, inhibited proliferation of GBM cells through a G2/M cell cycle arrest via inhibition of polo-like kinase 1 (PLK1) signalling pathway and down-modulation of Aurora kinases A and B, cyclin B1 and CDC25C. Moreover, tivozanib decreased adhesive potential of these cells through reduction of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28287096",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib is a potent inhibitor of VEGF-1, -2 and -3 receptors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive to 5-fluorouracil in preclinical models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25591799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Introduction Tivozanib is a novel tyrosine kinase inhibitor (TKI) which inhibits vascular endothelial growth factor (VEGF) receptors-1, -2, and -3 at nanomolar concentrations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013465",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tivozanib, a pan-inhibitor of VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell cycle arrest and apoptotic cell death.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28383032",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "vascular endothelial growth factor receptors"
}